Global Advanced Therapy Medicinal Product (ATMP) Market - 2023-2030
Global Advanced Therapy Medicinal Product(ATMP) Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Advanced therapy medicinal products (ATMPs) are medicines that are produced based on genes, tissues, or cells. They offer new opportunities for the treatment of disease and injury. The ATMPs are classified into gene therapy medicines, somatic cell therapy medicines, and tissue-engineered medicines.
Advanced therapy medicinal products (ATMPs) constitute an innovative class of heterogeneous research-driven biopharmaceuticals. The drugs are based on cell therapy and gene therapy, the therapies in combination with medical devices are called tissue-engineered products.
Market Dynamics: Drivers & Restraints
The increase in the number of research and developmental activities
The increase in the novel approaches to treating genetic disorders and increased investments in the research for developing new drugs and treatment procedures is expected to drive the market growth.
For instance, according to the National Center for Science and Engineering Statistics, it is estimated that Research and development spending by academic institutions totaled $97.8 billion in 2022, an increase of $8.0 billion from 2021
For instance, Urgo launched a $107M artificial skin engineering laboratory novel tissue engineering laboratory to create artificial skin to help the health care professionals in the effective treatment of severe wounds and quickly curing patients. Thus, the increasing research and increase in investments in introducing new products are expected to drive market growth in the forecast period.
Restraint
Stringent regulations for the approvals
The stringent regulations associated with the approvals of the medicine are expected to decline the market growth. The risks associated with gene corrections and treatments are also a factor that hamper market growth.
Segment Analysis
The global advanced therapy medicinal product (ATMP) market is segmented based on type, disease indication, and region.
Gene therapy medicines segment accounted for 49.5% of the market share
Gene therapy medicines have been holding a dominant position in the market share. This is due to the increase in genetic disorders and also the efficiency of the treatment to treat the disorder. Gene therapy drugs such as siRNA, shRNA, antisense oligonucleotide, CRISPR/Cas9 system, plasmid DNA, and miRNA have shown great potential in biomedical applications.
Gene therapy is a new generation of medicine where a functioning gene is delivered to a targeted tissue in the body to produce a missing or nonfunctioning protein. Based on the cells and genes of the individual the medicines that target the incorrect gene are produced. Most of the disease conditions can be cured or prevented by gene therapy medicine.
For instance, according to the NIH report in 2021, it is estimated that genetic therapy medicine management showed 30–40% complete response and 50–60% partial response with a total response rate of 90%–96% in different therapeutic uses. Thus, the above factors are expected to hold the segment in the dominant market share.
Geographical Analysis
North America is expected to hold a significant position in the global advanced therapy medicinal product (ATMP) market share
North America is expected to hold a dominant position in the market share due to the increase in genetic disorders. An increase in genetic disorders in the region is boosting research and paving the way for the development of new drugs.
For instance, According to the CDC report in 2022, Cystic fibrosis (CF) is a genetic disorder that causes problems with breathing and digestion. CF affects about 35,000 people in the United States. Approximately 1,000 new cases of CF are diagnosed each year in the U.S.
Additionally, researchers estimated that 18,000 males in the United States had hemophilia. Additionally, about two-thirds of these individuals received care in the U.S. network of specialized and comprehensive Hemophilia Treatment Centers (HTCs). Thus, the above factors are expected to drive the region’s market growth in the forecast period.
COVID-19 Impact Analysis
COVID-19 has had a moderate impact on the growth of the market. The R&D activities have been reduced during the COVID-19, this is due to the shift of the interest and need of the introduction of new drugs for the treatment of COVID-19. The supply chains have been interrupted during the lockdown period.
Market Segmentation
By Type
• Gene Therapy Medicines
• Somatic Cell Therapy Medicines
• Tissue Engineered Medicines
By Disease Indication
• Cancer
• Cardiovascular diseases
• Musculoskeletal
• Immune System and Inflammation
• Neurology
• Others
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The leading companies with a significant market share include RHEACELL., BioTissue Technologies GmbH, Mukocell GmbH, Orchard Therapeutics plc., Kite Pharma EU B.V., Bristol-Myers Squibb Pharma EEIG, Novartis Europharm Limited, and Amgen Europe B.V. among others.
Why Purchase the Report?
• To visualize the global advanced therapy medicinal product (ATMP) market segmentation based on type, disease indication, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of advanced therapy medicinal product market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global advanced therapy medicinal product market report would provide approximately 47 tables, 48 figures, and 176 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Type
- 3.2. Snippet by Disease Indication
- 3.3. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. The increase in the number of research and developmental activities
- 4.1.1.2. XX
- 4.1.2. Restraints
- 4.1.2.1. Stringent regulations for the approvals
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Russia-Ukraine War Impact Analysis
- 5.6. DMI Opinion
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
- 7.2. Gene Therapy Medicines*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Somatic Cell Therapy Medicines
- 7.4. Tissue Engineered Medicines
- 8. By Disease Indication
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 8.1.2. Market Attractiveness Index, By Disease Indication
- 8.2. Cancer *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Cardiovascular diseases
- 8.4. Musculoskeletal
- 8.5. Immune System and Inflammation
- 8.6. Neurology
- 8.7. Others
- 9. By Region
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.2.5.1. U.S.
- 9.2.5.2. Canada
- 9.2.5.3. Mexico
- 9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.3.5.1. Germany
- 9.3.5.2. UK
- 9.3.5.3. France
- 9.3.5.4. Italy
- 9.3.5.5. Spain
- 9.3.5.6. Rest of Europe
- 9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.4.5.1. Brazil
- 9.4.5.2. Argentina
- 9.4.5.3. Rest of South America
- 9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.5.5.1. China
- 9.5.5.2. India
- 9.5.5.3. Japan
- 9.5.5.4. Australia
- 9.5.5.5. Rest of Asia-Pacific
- 9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
- 10. Competitive Landscape
- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis
- 11. Company Profiles
- 11.1. RHEACELL. *
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
- 11.2. BioTissue Technologies GmbH
- 11.3. Mukocell GmbH
- 11.4. Orchard Therapeutics plc.
- 11.5. Kite Pharma EU B.V.
- 11.6. Bristol-Myers Squibb Pharma EEIG
- 11.7. Novartis Europharm Limited
- 11.8. Amgen Europe B.V.
- LIST NOT EXHAUSTIVE
- 12. Appendix
- 12.1. About Us and Services
- 12.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook